Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on AbbVie (NYSE:ABBV) and raised the price target from $163 to $170.
July 28, 2023 | 5:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's price target has been raised from $163 to $170 by Piper Sandler, which maintains an Overweight rating on the stock.
The raised price target indicates that the analyst sees potential for the stock's price to increase. This could lead to positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100